LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA – Trademark Portfolio

Entity Type: 16

LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include WELIV. The owner is based in Itapeva, Minas Gerais.

RUA HEITOR CLEMENTE, número 200

Itapeva, Minas Gerais 37655-000 , BR

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

WELIV
WELIV
Registered 2024

Trademark Classifications

LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA have?

LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA file in?

LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA's most well-known trademarks?

LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA's registered trademark portfolio includes well-known marks such as WELIV. These are among 1 currently registered trademark in the portfolio.

What is LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA's trademark registration success rate?

LIPOLABS NEGOCIOS DE SAÚDE E BEM ESTAR LTDA has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.